



# SOMALIA

Number of new cases

**10 681**

Number of deaths


**8 038**

Number of prevalent cases (5-year)

**12 983**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	8 395 755	8 446 050	16 841 805
<b>Incidence*</b>			
Number of new cancer cases	3 998	6 683	10 681
Age-standardized incidence rate	95.4	145.9	121.0
Risk of developing cancer before the age of 75 years (cum. risk %)	9.7	14.9	12.4
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum Leukaemia	Breast Cervix uteri Colorectum	Breast Cervix uteri Colorectum
<b>Mortality*</b>			
Number of cancer deaths	3 104	4 934	8 038
Age-standardized mortality rate	78.1	112.6	95.5
Risk of dying from cancer before the age of 75 years (cum. risk %)	7.9	12.0	10.1
Top 3 leading cancers (ranked by deaths)**	Prostate Colorectum Leukaemia	Breast Cervix uteri Colorectum	Breast Cervix uteri Colorectum
<b>Prevalence*</b>			
5-year prevalent cases	4 658	8 325	12 983



## Top 5 most frequent cancers\*\*

**Males**




Total: 3 998

Rank	Cancer site	Number of cases	Percent
1st	Prostate	623	15.6%
2nd	Colorectum	380	9.5%
3rd	Leukaemia	299	7.5%
4th	NHL	264	6.6%
5th	Stomach	184	4.6%
-	Others	2 248	56.2%

Number of new cases in 2022, males, all ages

**Females**




Total: 6 683

Rank	Cancer site	Number of cases	Percent
1st	Breast	1 811	27.1%
2nd	Cervix uteri	1 167	17.5%
3rd	Colorectum	375	5.6%
4th	Ovary	311	4.7%
5th	Leukaemia	240	3.6%
-	Others	2 779	41.6%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 10 681

Rank	Cancer site	Number of cases	Percent
1st	Breast	1 811	17.0%
2nd	Cervix uteri	1 167	10.9%
3rd	Colorectum	755	7.1%
4th	Prostate	623	5.8%
5th	Leukaemia	539	5.0%
-	Others	5 786	54.2%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	1 811	1	17.0	4.1	1 165	1	14.5	2.8	2 234	26.5
Cervix uteri	1 167	2	10.9	3.0	919	2	11.4	2.5	1 402	16.6
Colorectum	755	3	7.1	1.1	623	3	7.8	0.89	852	5.1
Prostate	623	4	5.8	1.9	413	5	5.1	1.2	572	6.8
Leukaemia	539	5	5.0	0.44	416	4	5.2	0.39	660	3.9
NHL	465	6	4.4	0.43	322	8	4.0	0.34	604	3.6
Oesophagus	409	7	3.8	0.62	393	6	4.9	0.59	621	3.7
Stomach	391	8	3.7	0.56	367	7	4.6	0.53	618	3.7
Ovary	311	9	2.9	0.79	238	11	3.0	0.68	354	4.2
Liver	301	10	2.8	0.43	296	9	3.7	0.42	452	2.7
Lung	271	11	2.5	0.42	252	10	3.1	0.40	413	2.5
Thyroid	267	12	2.5	0.30	98	18	1.2	0.15	344	2.0
Kidney	224	13	2.1	0.20	156	12	1.9	0.15	284	1.7
Lip, oral cavity	189	14	1.8	0.26	146	13	1.8	0.22	225	1.3
Bladder	172	15	1.6	0.25	115	17	1.4	0.16	205	1.2
Nasopharynx	162	16	1.5	0.17	126	16	1.6	0.15	205	1.2
Brain CNS	152	17	1.4	0.15	142	15	1.8	0.15	221	1.3
Pancreas	149	18	1.4	0.23	145	14	1.8	0.22	176	1.1
Corpus uteri	144	19	1.3	0.45	59	22	0.73	0.19	193	2.3
Hodgkin lymphoma	108	20	1.0	0.06	59	22	0.73	0.03	154	0.91
Multiple myeloma	97	21	0.91	0.15	87	19	1.1	0.14	107	0.64
Larynx	89	22	0.83	0.14	69	20	0.86	0.12	105	0.62
Kaposi sarcoma	80	23	0.75	0.07	46	24	0.57	0.05	109	0.65
Gallbladder	70	24	0.66	0.12	66	21	0.82	0.11	110	0.65
Salivary glands	51	25	0.48	0.06	39	25	0.49	0.05	64	0.38
Vulva	51	25	0.48	0.11	33	26	0.41	0.08	67	0.79
Melanoma	45	27	0.42	0.06	23	27	0.29	0.03	56	0.33
Vagina	26	28	0.24	0.08	18	28	0.22	0.06	29	0.34
Testis	23	29	0.22	0.03	12	31	0.15	0.02	31	0.37
Oropharynx	19	30	0.18	0.03	13	30	0.16	0.03	19	0.11
Hypopharynx	19	30	0.18	0.03	17	29	0.21	0.03	15	0.09
Penis	3	32	0.03	0.01	2	32	0.03	0.00	3	0.04
<b>All cancers</b>	<b>10 681</b>	-	-	<b>12.4</b>	<b>8 038</b>	-	-	<b>10.1</b>	<b>12 983</b>	-
<b>All cancers excl. NMSC</b>	<b>10 423</b>	-	-	<b>12.1</b>	<b>7 886</b>	-	-	<b>9.8</b>	<b>12 636</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** No data: the rates are those of neighbouring countries or registries in the same area

### Mortality

**Country-specific data source:** No data  
**Method:** Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

